AXSM Relative Valuation
AXSM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AXSM is overvalued; if below, it's undervalued.
Historical Valuation
Axsome Therapeutics Inc (AXSM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.33 is considered Undervalued compared with the five-year average of -18.09. The fair price of Axsome Therapeutics Inc (AXSM) is between 219.00 to 236.44 according to relative valuation methord. Compared to the current price of 111.70 USD , Axsome Therapeutics Inc is Undervalued By 49%.
Relative Value
Fair Zone
219.00-236.44
Current Price：111.70
49%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
103.33
P/B
Median3y
44.40
Median5y
42.45
-2.14
FCF Yield
Median3y
-3.86
Median5y
-4.63
Competitors Valuation Multiple
The average P/S ratio for AXSM's competitors is 43.41, providing a benchmark for relative valuation. Axsome Therapeutics Inc Corp (AXSM) exhibits a P/S ratio of 8.33, which is -80.81% above the industry average. Given its robust revenue growth of 61.95%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Axsome Therapeutics Inc (AXSM) currently overvalued or undervalued?
What is Axsome Therapeutics Inc (AXSM) fair value?
How does AXSM's valuation metrics compare to the industry average?
What is the current P/B ratio for Axsome Therapeutics Inc (AXSM) as of Jul 20 2025?
What is the current FCF Yield for Axsome Therapeutics Inc (AXSM) as of Jul 20 2025?
What is the current Forward P/E ratio for Axsome Therapeutics Inc (AXSM) as of Jul 20 2025?